Braxia Scientific CEO Dr. Roger McIntyre joined Steve Darling from Proactive to share ground-breaking news that the first Health Canada-approved multiple-dose psilocybin clinical trial has commenced with the first patients dosed in November 2021.
Dr. McIntyre telling Proactive this is the only Health Canada approved psilocybin trial in Canada that is actively recruiting participants at this time. This trial is being conducted at the Canadian Rapid Treatment Center of Excellence and includes adults with treatment-resistant depression as part of bipolar or unipolar disorder, who have not benefited from multiple conventional treatments.